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Abstract The sleeping sickness parasite, Trypanosoma
brucei, must differentiate in response to the changing
environments that it encounters during its complex life
cycle. One developmental form, the bloodstream stumpy
stage, plays an important role in infection dynamics and
transmission of the parasite. Recent advances have shed
light on the molecular mechanisms by which these stumpy
forms differentiate as they are transmitted from the
mammalian host to the insect vector of sleeping sickness,
tsetse flies. These molecular advances now provide im-
proved experimental tools for the study of stumpy
formation and function within the mammalian bloodstream.
They also offer new routes to therapy via high-throughput
screens for agents that accelerate parasite development.
Here, we shall discuss the recent advances that have been
made and the prospects for future research now available.
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Sleeping sickness: an ancient and current disease
The tropical parasite Trypanosoma brucei is the causative
agent of both human African trypanosomiasis (HAT, or
sleeping sickness) and the livestock disease, nagana. Over
50,000 people throughout 36 countries in sub-Saharan
Africa are currently estimated to be infected [1]. The initial
stage of disease, established when an individual is bitten by
an infected tsetse fly, generates a local chancre at the bite
site with this being followed by the proliferation of the
parasite in the bloodstream resulting in fever and joint pain.
At this stage, the disease is often undiagnosed and, as such,
untreated, despite the availability of (albeit rather old) drugs
such as suramin (for Trypanosoma brucei rhodesiense or
acute sleeping sickness) and pentamidine (for Trypanosoma
brucei gambiense or chronic sleeping sickness). Later, the
parasites cross the blood–brain barrier to infect the central
nervous system, causing disturbance to the patient's sleep
patterns, as well as causing confusion and difficulty with
coordination. The current drug treatments for the later stage
of the disease are difficult to administer, requiring a
rigorous hospital regime, and all have associated toxicity.
For example, melarsoprol is an arsenic-based treatment
developed in 1949 that kills 3–10% of patients and has
increasing incidence of drug resistance in the parasite
population. A more recently developed treatment for T.
brucei gambiense only, eflornithine, is less toxic, but
requires high doses and intravenous administration. None-
theless, without treatment, trypanosome infection is always
fatal. The clinical features and disease treatments of HAT
are discussed in more detail in [1].
The ability of trypanosomes to infect both domestic and
wild animals means that non-human hosts in affected
regions can act as a reservoir for the parasite, confounding
control of the disease. Moreover, vaccination approaches
have not been considered feasible because these parasites
evade mammalian immune responses by frequently chang-
ing the proteins on their surface in an extreme form of
antigenic variation. Due to the severity and prevalence of
the disease, as well as the lack of efficient disease
management, African trypanosomiasis remains an impor-
tant public health issue and is considered by the World
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The biology of disease spread
Trypanosomes differentiate between distinct life stages in
order to prepare for, and adapt to, the different environ-
ments they encounter during their life cycle [2, 3]. During
the bloodstream stage of the life cycle, trypanosomes exist
as either proliferative ‘slender forms’ or non-proliferative,
transmissible, ‘stumpy forms’ [2, 3] (Fig. 1), with transi-
tional forms between these two types being described as
‘intermediate’ forms. The proportion of these types changes
during the course of infection, this apparently being
governed by the density of parasites in the blood. The
bloodstream trypanosome population is adapted to promote
parasite maintenance in the mammalian blood and trans-
mission to tsetse flies. Thus, the proliferation of slender
forms contributes to the establishment of parasite numbers
in the blood and, through antigen variation, to immune
evasion. In contrast, the irreversible division-arrest of
stumpy forms acts to control the expansion of parasite
numbers in the mammalian bloodstream and so prolongs
host survival. This, combined with the preferential survival
and the adaptations for differentiation of stumpy forms
upon tsetse uptake, increases the probability of disease
transmission [4].
As the dynamic balance between slender and stumpy
forms in mammalian hosts plays a pivotal role in
trypanosome infection and transmission, understanding the
molecular events implicit in the slender to stumpy form
transition and their subsequent differentiation to tsetse
midgut forms (procyclic forms) is of interest and impor-
tance, though poorly understood.
Adaptation of stumpy forms for parasite transmission
When a tsetse fly ingests a trypanosome-infected blood-
meal, both slender and stumpy form parasites enter the
tsetse midgut. Although subject to some controversy [5], it
is generally thought that stumpy forms are pre-adapted to
life in the tsetse midgut, and only they differentiate
efficiently to the tsetse midgut procyclic form [3]. Cyto-
logical evidence based on in vitro differentiation experi-
Fig. 1 A simplified depiction of the T. brucei life cycle. In the
bloodstream of the mammalian host, slender forms proliferate. As
density increases, the parasites produce stumpy induction factor (SIF)
which induces differentiation of a proportion of slender forms to
stumpy forms. Stumpy forms are pre-adapted to life in the tsetse
vector: they are cell cycle-arrested and have elaborated mitochondrial
activity. Upon uptake in a tsetse blood-meal, stumpy forms differen-
tiate into the proliferative procyclic forms in response to cold shock
and cis-aconitate or citrate (CCA) in the tsetse midgut. Other signals
such as proteases or pH stress may also contribute, as does inhibition
of the tyrosine phosphatase, TbPTP1. Further differentiation events
occur in the tsetse to produce mature metacyclic forms in the salivary
glands. These are pre-adapted to life in the mammalian host
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to procyclic forms from a given point in the cell cycle,
namely within the G1, or the quiescent G0, phase [6]. As
stumpy forms are uniformly arrested as a population in G0/
G1 and can accumulate to near homogeneity in experimen-
tal infections, this allows for their efficient and synchronous
differentiation to procyclic forms. In contrast, proliferative
slender cell populations are asynchronous in their cell cycle
and must reach G0/G1 before differentiation [7]. Addition-
ally, as cells enter the tsetse midgut, they are exposed to
harmful proteases and changes in their environmental pH.
The stumpy forms are more resistant than slender forms to
the effects of such stresses [8] and, as such, are more likely
to endure the transition from the bloodstream to the tsetse
midgut. Moreover, in the glucose-rich mammalian blood-
stream, slender cells obtain their energy entirely via
glycolysis [9] and, as a result, the mitochondrion of slender
cells is relatively inactive [3]. In intermediate and stumpy
forms, however, the mitochondrion is elaborated and
mitochondrial enzymes are partially expressed [3, 9]. This
enables them to quickly begin oxidative phosphorylation as
they enter the glucose-poor tsetse midgut [3, 9].
Stumpy cells also persist longer than slender cells in the
face of the developing immune response in the mammalian
bloodstream [10, 11], as well as in the tsetse midgut. This is
probably not caused by antigenic variation: being irrevers-
ibly arrested in the bloodstream, stumpy forms are unlikely
to be able to undergo the DNA recombination events
important for antigen switching. Rather, they withstand
antibody clearance more effectively than slender cells
because they preferentially clear bound antibody by
hydrodynamic flow, whereby parasite-bound immunoglob-
ulin is swept backward by the swimming action of the
trypanosome in the blood and is then internalised and
degraded [12].
The molecular mechanism by which bloodstream trypa-
nosomes perceive their change in environment and initiate
differentiation to procyclic forms once in the tsetse fly has
been elusive, until recently. It has long been known that the
use of high concentrations (>3 mM) of citrate orcis-aconitate
(CCA) could induce differentiation of bloodstream form
trypanosomes to procyclic forms in vitro [13–15]. The
biological relevance of this signal was in doubt, however, as
these levels exceed the concentrations of CCA that a
trypanosome would be exposed to in the tsetse midgut
[15]. However, in 2004, Engstler and Boshart discovered
that a drop in temperature from 37°C to 20°C could
significantly increase trypanosome sensitivity to CCA,
potentially matching levels present within the tsetse blood-
meal [16]. Since this temperature drop was compatible with
that encountered by trypanosomes as they entered tsetse
flies feeding at the cooler ambient temperatures of dusk or
dawn, CCA could be considered physiologically relevant.
Since temperature drop also allows some molecules regu-
lated access to the parasite surface, Engstler and Boshart
proposed a model whereby an unknown surface protein
responsible for the reception of the differentiation signal
would be retained within the cell in the bloodstream (i.e.
when at 37°C) and then trafficked to the cell surface in
response to the cooler temperatures associated with tsetse
uptake [16, 17]. The molecular basis of this model,
however, was unknown until a gene family encoding surface
carboxylate transporters known as PAD proteins (proteins
associated with differentiation) was recently identified [18].
Indeed, two of the encoded PAD proteins (PAD1 and PAD2)
were shown to be expressed in stumpy forms but not in
slender forms and were found to be required for perception
of CCA at physiological concentrations [18]. Matching the
predictions of Engstler and Boshart, PAD2 was also
demonstrated to be confined to the parasite's flagellar pocket
region at 37°C but released to the cell surface at 20°C,
thereby demonstrating the redistribution of the transporter in
response to cold shock [16, 18]. Such thermoregulatory
events are increasingly recognised as being important in
insect-borne parasites, including in leishmania and malaria
[19, 20].
The differential expression and localisation of the PAD
proteins provide two levels of control during the differen-
tiation to procyclic forms (Fig. 2). First, differential
expression of PAD proteins between slender and stumpy
forms ensures only the pre-adapted transmissible stumpy
forms are able to receive the differentiation signal. Second,
the differential localisation of PAD2 between stumpy cells
at 37°C and 20°C ensures that only cells in the appropriate
environment (i.e. the tsetse midgut) are able to receive the
signal. As citrate is present in blood at ∼130 µM [21], this
secondary control point could be crucial to prevent
premature differentiation to procyclic forms whilst within
the host, this signal only being detected upon temperature
reduction in the tsetse blood-meal.
Before the discovery of PAD proteins, it was already
established that the activity of a protein tyrosine phospha-
tase, TbPTP1, inhibits the differentiation of stumpy forms
whilst in the bloodstream, this block being removed upon
uptake by the tsetse fly [22]. Hence, it may be that TbPTP1
acts downstream of the PAD proteins as an effector of the
CCA signal (Fig. 1) or it may act via a parallel pathway,
providing additional stringent control of differentiation.
Similarly, exposure to proteases [15, 23] or pH stress [24]
in the tsetse midgut might also trigger differentiation, either
in a complementary manner or as independent cues [24].
Although the role of these other environmental cues is yet
to be fully understood, the discovery of the PAD proteins
provides the first molecular insight into the environmental
sensing mechanisms used by the stumpy form to perceive
transmission and so initiate differentiation.
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One of the key reasons that the differentiation from
bloodstream forms to procyclic forms has been so well-
studied is that there are clear molecular markers to
distinguish each developmental stage. Furthermore, the
development between the bloodstream and procyclic forms
can be easily mimicked in vitro. Contrasting with this, the
absence of markers distinguishing slender from stumpy
forms has hindered our understanding of the transmission
biology of trypanosomes, as has the difficulty in success-
fully generating stumpy forms in culture. In earlier studies,
various markers have been used to identify stumpy forms,
including morphology, mitochondrial activation, cell cycle
arrest and the capacity of cells to differentiate synchro-
nously to the procyclic form [25–29]. These assays,
however, are far from ideal. For example, analysis by
morphology is subjective and time-consuming and is
complicated by the presence of morphologically intermedi-
ate forms in the population. Similarly, differentiation
analyses are time-dependent and require population assays,
rather than the analysis of individual cells. Finally,
mitochondrial activation, often visualised through the
activity of dihydrolipoamide dehydrogenase in the diapho-
rase assay, may also be activated under non-physiological
stress conditions. With the identification of PAD1 as a
surface molecule that identifies cells that are functionally
competent for transmission [18], as well as developments in
parasite culture and transfection [30], the route has been
opened up to dissect trypanosome transmissibility at the
level of individual cells as well as in the infecting parasite
population.
Differentiation of the individual parasite
Differentiation between life cycle stages and the progres-
sion of the cell cycle are intimately linked in trypanosomes
[7, 22]. As mentioned above, stumpy forms are cell cycle-
arrested in G0/G1 but derived from proliferative slender
forms. This transition, therefore, requires exit from the cell
cycle, morphological change and stumpy-specific gene
expression and has been studied both experimentally and
by mathematical modelling [7, 29, 31]. From these studies,
it appears that the commitment of a slender cell to
differentiate to a stumpy form precedes a final cell division
and morphological change [7, 29]. However, the discovery
of PAD1 as a molecular marker for stumpy forms enables
the events of cell cycle exit and stumpy formation to be
tracked at the level of an individual cell, providing a
temporal map of the steps leading to transmission compe-
tence. Similarly, the signalling pathways that generate
stumpy forms from slender forms can be investigated. This
transition can occur independently of the host [32, 33] and
correlates with increased cell density [28, 33, 34], with
parasite–parasite signalling operating through a form of
quorum sensing. This is proposed to occur through the
production by slender forms of a signal, termed stumpy
induction factor (SIF), which accumulates and stimulates
stumpy formation as parasite numbers increase [33]. The
identity of SIF and the molecular mechanisms of its
reception are currently unknown. It was thought that the
SIF signal was transmitted via the cAMP pathway, since
cell-permeable cAMP can mimic the action of SIF (Fig. 1)
[33]. However, more recent evidence suggests that hydro-
lysis products of cAMP also function, arguing against a
Fig. 2 PAD protein expression and localisation act as checkpoints for
differentiation. A summary of the expression of PAD proteins and the
consequences for trypanosome differentiation events, based on the
predictive model of Engstler and Boshart (2004) [16]. Slender cells
proliferate in the bloodstream of the mammalian host. As parasite
density increases, slender cells produce SIF which induces production
of stumpy forms. Stumpy forms express PAD proteins (denoted by X),
whereas slender forms do not. This ensures that only the transmissible
stumpy forms are able to detect the differentiation signal. Upon
ingestion in a tsetse blood-meal and exposure to a drop in temperature,
there is up-regulation and a relocation of at least one PAD protein
(PAD2) to the cell surface. Retention of PAD2 within the cell prior to
cold shock ensures stumpy forms do not differentiate prematurely.
Stumpy forms then differentiate to procyclic forms synchronously in
response to CCA. Slender forms do not perceive the signal and are
sensitive to proteolytic and potential pH stress in the tsetse midgut and
therefore do not survive
868 J Mol Med (2010) 88:865–871conventional cAMP signalling pathway [27]. Additional
compounds such as troglitazone [26] and Z-Phe-Ala-CHN2
[35] have also been proposed to mimic SIF activity in vitro,
inhibiting cell growth and generating morphologically
‘stumpy-like’ forms. The biological significance of these
different treatments, however, has been difficult to assess in
the absence of a functional molecular marker for stumpy
forms. Hence, the identification of PAD1 and its detection
either by antibody or in transgenic reporter assays now
enables SIF, or SIF mimics, to be tracked in high-
throughput assays and identified.
Differentiation of the population
PAD1 also provides a route to analyse the proportions of
slender and stumpy forms in infections and to understand
how the dynamics of these change throughout the course of
a classical chronic infection. As trypanosome infections last
from months to years, each infected individual can act as a
reservoir for the disease for a considerable period of time.
However, the degree of periodicity in their transmission
capacity is poorly understood but potentially vital in a
context where tsetse bites are rare or show seasonality [17].
Furthermore, through mathematic modelling, it has been
predicted that the production of stumpy forms is a key
contributor to the ordered expression of distinct antigenic
variants that sustain chronic trypanosome infections [36].
This, combined with the likelihood of co-infection with
different trypanosome strains during the course of a chronic
infection, generates the potential for complex infection
dynamics with important possible implications for disease
progression and transmission in endemic areas. With the
availability of a marker for the transmission stage,
quantitative models for the dynamics of slender and stumpy
parasites as a proportion of the total parasite numbers over
time can be generated and the consequences of potential
therapeutic strategies predicted.
Accelerated parasite development as a therapeutic tool
The identification of a molecular marker that distinguishes
the non-proliferative stumpy form provides the ability to
develop high-throughput screens for compounds that
accelerate stumpy formation at abnormally low parasite
density. Genetically modified reporter lines could provide
simple assays for enhanced stumpy formation accessible to
screening with small molecule or natural product libraries.
If administrable compounds were identified that are able to
force the irreversible differentiation of slender forms to
stumpy forms at low levels of parasitaemia, then this could
have potential therapeutic consequences.
Although accelerated parasite development has the
potential to reduce host parasitaemia, it also has the potential
to increase the transmission potential of the population
through increasing the proportion of stumpy forms. The
extent of this risk depends on several factors: the density of
parasites in the bloodstream, the number of parasites
required to infect a tsetse fly and the efficiency of accelerated
development. Assuming a typical parasitaemia in cattle of
10
5 parasites/ml [37] and an infective dose to tsetse under
optimal conditions of one trypanosome [38], then a
reduction in parasite numbers of at least three orders of
magnitude would be required to minimise the probability of
parasite transmission in a tsetse blood-meal. However, in
the field, chronic infections of cattle can exhibit refractory
periods when there are insufficient parasites for tsetse
transmission, suggesting that the parasites may be on the
threshold of transmissibility, particularly when com-
Fig. 3 Accelerated parasite development as a route to limiting
parasite transmission and parasitaemia. In the normal course of
infection, slender cells generate stumpy forms once parasite numbers
are sufficient to ensure transmission if taken up during a tsetse blood-
meal. By accelerating stumpy formation at a lower parasitaemia, the
parasite load in the host would be reduced, potentially reducing
pathogenicity. Furthermore, the consequent limitation in parasite
numbers would reduce the potential for parasite transmission during
a tsetse blood-meal
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blocking feasible. Moreover, if stumpy formation could be
driven to 100% efficiency, then the irreversible division-
arrest of these forms would ensure complete parasite
elimination through cell senescence within only a few
days, limiting the risks of enhanced transmission and
providing a curative regime.
Clearly, without better understanding of the transmission
biology of trypanosomes in the field, the prospects for a
transmission blocking approach are difficult to assess. It is
satisfying, therefore, that the identification of stumpy
marker proteins such as PAD offers the ability to both
screen for new drugs to accelerate stumpy formation and to
refine the transmission models required to optimise their
potential deployment in the field.
Perspectives
Considerable progress has been made in recent years in
understanding trypanosome transmission at the level of
basic biology. However, these studies also have direct
application in the search for new therapies for trypano-
somes in the field. In particular, the ability of PAD
proteins to discriminate stumpy forms enables high-
throughput screens for compounds that accelerate stumpy
formation at low parasite density. By inducing stumpy
formation at low parasitaemia, the potential for parasite
transmission may be reduced (Fig. 3). Furthermore, with
a reduced parasite load, the host immune system may be
able to control the infection. Importantly, genetically
modified reporter lines could provide simple assays for
enhanced stumpy formation accessible to screening with
small molecule or natural product libraries. This offers
great potential for disrupting the normal life cycle
progression of the parasite and thereby restricting both
pathogenicity and transmissibility of these important
pathogens. As so often, an investment in basic knowledge
has provided an unexpected opportunity for the rational
screening for, and development of, novel therapeutic
approaches.
Acknowledgements This work is supported by a programme grant
from the Wellcome Trust to KRM and a Wellcome Trust PhD
studentship to PM. Work in the Matthews lab is carried out within the
Centre for Immunity, Infection and Evolution, supported by a
Strategic Award from the Wellcome Trust.
Conflict of interest declaration None declared.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Brun R, Blum J, Chappuis F, Burri C (2010) Human African
trypanosomiasis. Lancet 375:148–159
2. Vickerman K (1985) Developmental cycles and biology of
pathogenic trypanosomes. Brit Med Bull 41:105–114
3. Vickerman K (1965) Polymorphism and mitochondrial activity in
sleeping sickness trypanosomes. Nature 208:762–766
4. Tyler KM, Higgs PG, Matthews KR, Gull K (2001) Limitation of
Trypanosoma brucei parasitaemia results from density-dependent
parasite differentiation and parasite killing by the host immune
response. Proc Roy Soc B 268:2235–2243
5. Bass KE, Wang CC (1991) The in vitro differentiation of
pleomorphic Trypanosoma brucei from bloodstream into procy-
clic form requires neither intermediary nor short-stumpy stage.
Mol Biochem Parasitol 44:261–270
6. Ziegelbauer K, Quinten M, Schwarz H, Pearson TW, Overath P
(1990) Synchronous differentiation of Trypanosoma brucei from
bloodstream to procyclic forms in vitro. Eur J Biochem / FEBS
192:373–378
7. Matthews KR, Gull K (1994) Evidence for an interplay between cell
cycle progression and the initiation of differentiation between life
cycle forms of African trypanosomes. J Cell Biol 125:1147–1156
8. Nolan DP, Rolin S, Rodriguez JR, Van Den Abbeele J, Pays E
(2000) Slender and stumpy bloodstream forms of Trypanosoma
brucei display a differential response to extracellular acidic and
proteolytic stress. Eur J Biochem / FEBS 267:18–27
9. Priest JW, Hajduk SL (1994) Developmental regulation of
mitochondrial biogenesis in Trypanosoma brucei. J Bioenerg
Biomem 26:179–191
10. Balber AE (1972) Trypanosoma brucei: fluxes of the morpholog-
ical variants in intact and X-irradiated mice. Exp Parasitol
31:307–319
11. McLintock LM, Turner CM, Vickerman K (1993) Comparison of
the effects of immune killing mechanisms on Trypanosoma brucei
parasites of slender and stumpy morphology. Parasite imm
15:475–480
12. Engstler M, Pfohl P, Herminghaus S et al (2007) Hydrodynamic
flow-mediated protein sorting on the cell surface of trypanosomes.
Cell 131:505–515
13. Brun R, Schonenberger M (1981) Stimulating effect of citrate and
cis-aconitate on the transformation of Trypanosoma brucei
bloodstream forms to procyclic forms in vitro. Z Parasitenk
(Berlin, Germany) 66:17–24
14. Czichos J, Nonnengaesser C, Overath P (1986) Trypanosoma
brucei: cis-aconitate and temperature reduction as triggers of
synchronous transformation of bloodstream to procyclic trypo-
mastigotes in vitro. Exp Parasitol 62:283–291
15. Hunt M, Brun R, Kohler P (1994) Studies on compounds
promoting the in vitro transformation of Trypanosoma brucei
from bloodstream to procyclic forms. Parasitol Res 80:600–606
16. Engstler M, Boshart M (2004) Cold shock and regulation of surface
protein trafficking convey sensitization to inducers of stage
differentiation in Trypanosoma brucei.G e n e sD e v1 8 : 2 7 9 8 –2811
17. Baylis M (1997) The daily feeding rate of tsetse (Diptera:
Glossinidae) on cattle at Galana Ranch, Kenya and comparison
with trypanosomiasis incidence. Acta Trop 65:81–96
18. Dean SD, Marchetti R, Kirk K, Matthews K (2009) A surface
transporter family conveys the trypanosome differentiation signal.
Nature 459:213–217
19. Zilberstein D, Shapira M (1994) The role of pH and temperature
in the development of leishmania parasites. Ann Rev Microbiol
48:449–470
20. Fang J, McCutchan TF (2002) Thermoregulation in a parasite's
life cycle. Nature 418:742
870 J Mol Med (2010) 88:865–87121. Jacobs SL, Lee ND (1964) Determination of citric acid in serum
and urine using Br82. J Nucl Med 5:297–301
22. Szoor B, Wilson J, McElhinney H, Tabernero L, Matthews KR
(2006) Protein tyrosine phosphatase TbPTP1: a molecular switch
controlling life cycle differentiation in trypanosomes. J Cell Biol
175:293–303
23. Sbicego S, Vassella E, Kurath U, Blum B, Roditi I (1999) The use
of transgenic Trypanosoma brucei to identify compounds induc-
ing the differentiation of bloodstream forms to procyclic forms.
Mol Biochem Parasitol 104:311–322
24. Rolin S, Hancocq-Quertier J, Paturiaux-Hanocq F, Nolan DP, Pays
E (1998) Mild acid stress as a differentiation trigger in
Trypanosoma brucei. Mol Biochem Parasitol 93:251–262
25. Breidbach T, Ngazoa E, Steverding D (2002) Trypanosoma brucei:
in vitro slender-to-stumpy differentiation of culture-adapted,
monomorphic bloodstream forms. Exp Parasitol 101:223–230
26. Denninger V, Figarella K, Schonfeld C et al (2007) Troglitazone
induces differentiation in Trypanosoma brucei. Exp Cell research
313:1805–1819
27. Laxman S, Riechers A, Sadilek M, Schwede F, Beavo JA (2006)
Hydrolysis products of cAMP analogs cause transformation of
Trypanosoma brucei from slender to stumpy-like forms. Proc Natl
Acad Sci USA 103:19194–19199
28. Reuner B, Vassella E, Yutzy B, Boshart M (1997) Cell density
triggers slender to stumpy differentiation of Trypanosoma brucei
bloodstream forms in culture. Mol Biochem Parasitol 90:269–280
29. Tyler KM, Matthews KR, Gull K (1997) The bloodstream
differentiation-division of Trypanosoma brucei studied using
mitochondrial markers. Proc Roy Soc B 264:1481–1490
30. Vassella E, Boshart M (1996) High molecular mass agarose matrix
supports growth of bloodstream forms of pleomorphic Trypano-
soma brucei strains in axenic culture. Mol Biochem Parasitol
82:91–105
31. Savill NJ, Seed JR (2004) Mathematical and statistical analysis of
the Trypanosoma brucei slender to stumpy transition. Parasitology
128:53–67
32. Seed JR, Sechelski J (1988) Growth of pleomorphic Trypanosoma
brucei rhodesiense in irradiated inbred mice. J Parasitol 74:781–
789
33. Vassella E, Reuner B, Yutzy B, Boshart M (1997) Differentiation
of African trypanosomes is controlled by a density sensing
mechanism which signals cell cycle arrest via the cAMP pathway.
J Cell Sci 110(Pt 21):2661–2671
34. Hesse F, Selzer PM, Muhlstadt K, Duszenko M (1995) A novel
cultivation technique for long-term maintenance of bloodstream
form trypanosomes in vitro. Mol Biochem Parasitol 70:157–166
35. Scory S, Stierhof YD, Caffrey CR, Steverding D (2007) The
cysteine proteinase inhibitor Z-Phe-Ala-CHN2 alters cell mor-
phology and cell division activity of Trypanosoma brucei
bloodstream forms in vivo. Kinetoplastid Biol Dis 6:2
36. Lythgoe KA, Morrison LJ, Read AF, Barry JD (2007) Parasite-
intrinsic factors can explain ordered progression of trypanosome
antigenic variation. Proc Natl Acad Sci USA 104:8095–8100
37. Van den Bossche P, Ky-Zerbo A, Brandt J, Marcotty T, Geerts S,
De Deken R (2005) Transmissibility of Trypanosoma brucei
during its development in cattle. Trop Med Int Health 10:833–839
38. Maudlin I, Welburn SC (1989) A single trypanosome is sufficient
to infect a tsetse fly. Ann Trop Med Parasitol 83:431–433
J Mol Med (2010) 88:865–871 871